CSPC Innovation Pharmaceutical announced that the injectable CPO301 filed by CSPC Pharma Giant Stone BioPharmaceutical Co., Ltd. has obtained the fast track qualification granted by the US FDA. It is used to treat recurrent or metastatic squamous non-small cell lung cancer patients with high expression of epidermal growth factor receptor, who have experienced progression during or after receiving platinum-based chemotherapy and anti-PD-1 therapy.
新诺威：药物CPO301获美国FDA快速通道资格
CSPC Innovation Pharmaceutical: Drug CPO301 granted fast track qualification by the US FDA.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated